Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway.
Factors predisposing to extracellular matrix degradation associated with myocardial ischemia/reperfusion (IR) usually cause cell death. Recombinant human erythropoietin (EPO) protects the myocardium from IR, but whether it affects extracellular matrix (ECM) degradation is not known. This study examined the effect of the Jak2-ERK pathway, which is triggered by EPO, on the expression of matrix metalloproteinases (MMPs), tissue inhibitor of MMP 4 (TIMP-4), and collagen in post-ischemic hearts. Rat hearts were isolated and perfused in a Langendorff apparatus. IR was induced by 40 min of stopped flow and 120 min of aerobic reperfusion; EPO was added immediately before reperfusion. Compared to untreated controls, poor recovery of the left ventricular developed pressure (LVDP) was seen in IR hearts. IR resulted in myocyte injury measured by creatine kinase MB release and infarction. Western blot analysis showed increased levels of MMP-2 and MMP-9 and reduced levels of TIMP-4 and collagen III. IR rats given 5 IU/ml of EPO showed improved LVDP with reduced injury. EPO increased Jak2 and ERK activity, decreased MMP expression, increased TIMP-4 expression, and prevented collagen degradation in IR hearts. All these effects were blocked by the upstream ERK inhibitor, U0126 (5 microM). These observations show that EPO attenuates extracellular matrix degradation following IR and this may be the basis of the protection from cell death. Jak2-ERK phosphorylation may be an important signal in this process.
Chan
Chih-Yang
CY
Department of Surgery, Cardiovascular Division, Far Eastern Memorial Hospital, 21, Sec. 2, Nanya S. Road, Panchaio 220, Taiwan.
Chen
Yih-Sharng
YS
Lee
Hsang-Hsing
HH
Huang
Ho-Shiang
HS
Lai
Yih-Loong
YL
Chen
Chau-Fong
CF
Ma
Ming-Chieh
MC
D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D003094:Collagen / Q000096:biosynthesis; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004921:Erythropoietin / Q000494:pharmacology*; D005109:Extracellular Matrix / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology*; D005260:Female; D006321:Heart / Q000187:drug effects*; D066298:In Vitro Techniques; D053614:Janus Kinase 2 / Q000096:biosynthesis / Q000502:physiology*; D020782:Matrix Metalloproteinases / Q000096:biosynthesis; D015428:Myocardial Reperfusion Injury / Q000201:enzymology / Q000378:metabolism; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D019714:Tissue Inhibitor of Metalloproteinases / Q000096:biosynthesis; D016277:Ventricular Function, Left / Q000187:drug effects; D000097792:Tissue Inhibitor of Metalloproteinase-4
D002316:Cardiotonic Agents; D003094:Collagen; D004791:Enzyme Inhibitors; D004921:Erythropoietin; D048049:Extracellular Signal-Regulated MAP Kinases; D053614:Janus Kinase 2; D020782:Matrix Metalloproteinases; D011994:Recombinant Proteins; D019714:Tissue Inhibitor of Metalloproteinases; D000097792:Tissue Inhibitor of Metalloproteinase-4; C103998:epoetin beta; C507927:Jak2 protein, rat